NEW YORK (360Dx) – Interpace Diagnostics said this week that it has converted all of its remaining long-term secured outstanding debt into common stock. 

In March, the firm had announced that its outstanding secured debt arising from the acquisition of RedPath Integrated Pathology in 2014, and worth $9.34 million, was acquired for $8.9 million, or 95 percent of its face value, by an unnamed institutional investor. The deal involved a debt exchange for a $5.3 million secured convertible note and a $3.5 million secured note issued by Interpace.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.